0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Ly6E

Ly6E

Brief Information

Name:Lymphocyte antigen 6E
Target Synonym:Stem cell antigen 2,LY6E,Lymphocyte Antigen 6 Family Member E,Retinoic Acid Induced Gene E,Thymic Shared Antigen 1,SCA2,Lymphocyte Antigen 6E,9804,TSA-1,Retinoic acid-induced gene E protein,SCA-2,TSA1,Ly-6E,RIG-E,RIGE,Lymphocyte Antigen 6 Complex, Locus E
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 1 Clinical

Synonym Name

LY6E,Ly-6E,Ly6E,RIG-E,SCA-2,TSA-1,9804,RIGE,SCA2,TSA1

Background

Lymphocyte antigen 6E (LY6E), also known as RIG-E, SCA2 and TSA1. GPI-anchored cell surface protein that regulates T-lymphocytes proliferation, differentiation, and activation. Regulates the T-cell receptor (TCR) signaling by interacting with component CD3Z/CD247 at the plasma membrane, leading to CD3Z/CD247 phosphorylation modulation. Restricts the entry of human coronaviruses, including SARS-CoV, MERS-CoV and SARS-CoV-2, by interfering with spike protein-mediated membrane fusion. Plays also an essential role in placenta formation by acting as the main receptor for syncytin-A (SynA). Therefore, participates in the normal fusion of syncytiotrophoblast layer I (SynT-I) and in the proper morphogenesis of both fetal and maternal vasculatures within the placenta. May also act as a modulator of nicotinic acetylcholine receptors (nAChRs) activity.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
RG-7841 RG-7841; DLYE-5953A Phase 1 Clinical Genentech Inc Neoplasms Details

This web search service is supported by Google Inc.

totop